Abhishek Tripathi, M.D.

800-826-4673
Abhishek Tripathi, M.D.
Medical Oncologist
Clinical Expertise
  • Genitourinary Cancers
Research Area
  • Genitourinary Malignancies
Other Languages Spoken
Hindi
Academic Appointments
  • Associate Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Medical Oncology & Therapeutics Research
Prostate Cancer
Urologic Cancers
Bladder Cancer
Research Teams
Medical Oncology & Therapeutics Research

Medical oncologist Abhishek Tripathi, M.D., channeled his early interest in biology into a medical career with inspiration from his parents, who worked in health care. He strives to tailor treatment based on the unique details of each person’s cancer and considering their goals, values and preferences. 

Dr. Tripathi joined City of Hope in 2022 after serving on the faculty of the University of Oklahoma Stephenson Cancer Center, where he had leadership roles in multiple clinical trials, including four ongoing studies that he initiated as principal investigator. In addition, he has authored numerous peer-reviewed research publications. 

At the American Society of Clinical Oncology’s 2017 symposium on genitourinary cancers, Dr. Tripathi was recognized with the Conquer Cancer Foundation of ASCO Merit Award. He was also selected to participate in a competitive workshop on clinical cancer research presented by ASCO and the American Association for Clinical Research. During his fellowship in oncology/hematology at the University of Massachusetts, he served a stint as chief fellow.

Location

Education & Experience

Board Certifications
  • American Board of Internal Medicine
  • American Board of Internal Medicine: Hematology
  • American Board of Internal Medicine: Medical Oncology
Degrees

  • 2009, Bachelor of Medicine and Bachelor of Surgery (M.B.B.S), University of Delhi, Maulana Azad Medical College

Residency

  • 2014, Internal Medicine Residency, University of Massachusetts Medical School, Worcester, Massachusetts

Fellowship

  • 2020, Hematology-Oncology Fellowship, University of Massachusetts-Baystate Medical Center, Springfield, Massachusetts

Professional Experience

  • 2022-present   Associate Professor, Department of Medical Oncology & Therapeutics Research, 
    City of Hope, Duarte, California
     

  • 2017-2022  Assistant Professor of Medicine, Hematology/Oncology, University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma
     

Awards & Memberships

Awards

 

  • 2019, Faculty Mentorship Award, Section of Hematology-Oncology, University of Oklahoma
  • 2017, Conquer Cancer Foundation Merit Award, ASCO GU Cancers Symposium
  • 2016-2017, Chief Fellow, University of Massachusetts Baystate Medical Center

Memberships

  • American Society of Clinical Oncology
  • American Society of Hematology
  • ECOG-ACRIN Genitourinary Malignancies Committee
  • American Association for Cancer Research
  • Southwest Oncology Group Genitourinary Cancers Committee

Publications

  • Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park J. J, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Frobe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo G. D, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright J. L, Grivas P, Khaki AR. Response and outcomes to immune checkpoint inhibitors in advanced urothelial cancer based on prior intravesical Bacillus Calmette-Guerin. In press, Clin Genitourin Cancer 2021
  • Tripathi N, Agarwal N, Tripathi A. Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. Oncologist 2021; PMID: 34333836
  • Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V. S, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato D. J, Nelson A, Hoimes CJ, Shreck E, Gartrell B. A, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Frobe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright J. L, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int 2021; PMID: 34597472
  • Koshkin VS, Patel V. G, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham L. S, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis 2021; PMID: 34363009
  • Tripathi A, Khaki AR, Grivas P. Perioperative Immunotherapy in Muscle-invasive Bladder Cancer.Eur Urol Oncol 2021, PMID: 33642222
  • Bensen RC, Standke S. J, Colby DH, Kothapalli N. R, Le-McClain A. T, Patten MA, Tripathi A, Heinlen JE, Yang Z, Burgett AWG. Single Cell Mass Spectrometry Quantification of Anticancer Drugs: Proof of Concept in Cancer Patients. ACS Pharmacol Transl Sci 2021, PMID: 33615163
  • Esagian S. M, Khaki A. R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes C. J, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida, A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Frobe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes, BJU Int 2021; PMID: 33556233.
  •  Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Frobe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors, Eur Urol Oncol 2021; PMID: 33423945
  •  Tripathi A, Lin E, Xie W, Flaifel A, Steinharter JA, Stern Gatof EN, Bouchard G, Fleischer JH, Martinez-Chanza N, Gray C, Mantia C, Thompson, L, Wei XX, Giannakis M, McGregor BA, Choueiri T. K, Agarwal N, McDermott DF, Signoretti S, Harshman LC. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Can 2020; PMID: 33177176

View more publications

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.9
Show respect for what you say
4.9
Spend enough time with you
4.9
Rate provider 0-10
4.8
Recommend this provider office
07/25/24
The provider explained in understandable terms what my condition was and plans to resolve it. - Verified patient
07/25/24
This provider's Open Notes do not provide any details of our conversation, reflect the questions I had, his answers or my concerns. Basically zero open notes. Note what I expect from a COH doctor. - Verified patient
07/18/24
This visit was the first time seeing this provider. Per this first visit, most likely will refer this provider to others [...] - Verified patient
07/18/24
The medical staff at COH are friendly and gives positive encouragement - Verified patient
06/20/24
Liked the Dr. Very much - Verified patient